Skip to main content

Articles By Rachel Tate, DO

Winthrop RNL

Five Takeaways in PsA/SpA at RNL 2024

Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Here are my five key takeaways and clinical pearls. 

Read Article
RA Panel

Top 5 Clinical Pearls in RA Management

RheumNow Live 2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in Rheumatoid Arthritis."

Read Article
abdominal-pain-2821941_640.jpg

ICYMI: SpA Sleuths: The Case of Undiagnosed IBD

Abstract #0494 provides context to our continual search for better understanding of inflammatory bowel disease in patients with AS, nr-AxSpA, and PsA.

Read Article
abdominal-pain-2821941_640.jpg

SpA Sleuths: The Case of Undiagnosed IBD

Abstract #0494 provides context to our continual search for better understanding of inflammatory bowel disease in patients with AS, nr-AxSpA, and PsA.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy Updates That Will Change The Way I Practice

ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification.

Read Article
Biosimiars

ICYMI: The Biosimilar "Buy In"

The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients.  Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023.

Read Article
No stop

No is a complete sentence

No is a complete sentence. For context, I am a "yes" person, and I always have been.

Read Article
RT Rachel Tate

The Benefits of Networking

Networking provides the framework for an exchange of ideas and new opportunities that can actually open doors.

Read Article
Workforce

Rheumatology Workforce: Is it a Women’s Issue?

I recently sat down with Dr. Daniel Battafarano, chair of the ACR’s Workforce Solutions Committee, to discuss workforce study findings, their impact on the next few years, and proposed interventions to address these issues.

Read Article
Biosimiars

The Biosimilar "Buy In"

The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients.  Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023.

Read Article